Brind.

Serina Therapeutics' SER-270, a once-weekly injectable therapy, utilizes a proprietary long-acting platform.

2 reports, 2 independent Updated Jun 30

Gone quiet

Reports: 2
Developments: 2
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Serina Therapeutics' SER-270, a once-weekly injectable therapy, utilizes a proprietary long-acting platform.

Who's involved

What this event is mainly about

Karuna Therapeutics LivaNova Eli Lilly and Company

How it developed

Newest first. Tap a step to see who reported it.

Jun 30Gannet BioChem announced support for Serina's therapy development.1 source
- manilatimes.net
Aug 12Details Serina's SER-270 and the background of Stephen Brannan, who worked at LivaNova, Eli Lilly, and Karuna.1 source
- GlobeNewswire

Keep exploring

The entities involved

Karuna Therapeutics
biopharmaceutical company

Nothing else this week.
LivaNova
UK business

Nothing else this week.
Eli Lilly and Company
American pharmaceutical company
- ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
- The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59

Coverage

Newest first; wire copies grouped

Jun 30manilatimes.net
Aug 12GlobeNewswireSerina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: S